Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Endocrine Neoplasia Type 1 1 Coronary Disease 1

Interventions

Cyclophosphamide 297 Cisplatin 297 Paclitaxel 258 Radiotherapy 253 Fluorouracil 234 Carboplatin 234 Docetaxel 231 Doxorubicin 212 Dexamethasone 164 Gemcitabine 155 Vincristine 143 Etoposide 133 Leucovorin 132 Capecitabine 129 Bevacizumab 129 Prednisone 124 Rituximab 118 Methotrexate 117 Cytarabine 108 Filgrastim 99 Trastuzumab 98 Oxaliplatin 96 pembrolizumab 81 Pemetrexed 73 Epirubicin 70 Tamoxifen 69 Drug Therapy 69 Irinotecan 65 Granulocyte Colony-Stimulating Factor 60 Nivolumab 57

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × evolocumab × Clear all

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡